Fennec Pharmaceuticals (TSE:FRX) Raised to “Strong-Buy” at Stephens

Fennec Pharmaceuticals (TSE:FRX) was upgraded by investment analysts at Stephens to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

Fennec Pharmaceuticals Stock Up 0.2 %

FRX opened at C$5.69 on Monday. The stock’s fifty day simple moving average is C$6.44 and its 200 day simple moving average is C$8.08. Fennec Pharmaceuticals has a 1-year low of C$5.65 and a 1-year high of C$15.43. The stock has a market cap of C$155.68 million, a PE ratio of 56.90 and a beta of 0.25. The company has a current ratio of 8.02, a quick ratio of 10.17 and a debt-to-equity ratio of 1,040.68.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.